67 related articles for article (PubMed ID: 18090297)
21. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
22. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Yan Q; Hruz PW
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):398-403. PubMed ID: 16280693
[TBL] [Abstract][Full Text] [Related]
23. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
24. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
25. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
26. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
27. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
[TBL] [Abstract][Full Text] [Related]
28. CASTLE study showed similar efficacy.
AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342
[No Abstract] [Full Text] [Related]
29. HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Hruz PW; Yan Q; Struthers H; Jay PY
FASEB J; 2008 Jul; 22(7):2161-7. PubMed ID: 18256305
[TBL] [Abstract][Full Text] [Related]
30. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
[TBL] [Abstract][Full Text] [Related]
31. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.
Bonora S; Lanzafame M; D'Avolio A; Trentini L; Lattuada E; Concia E; Di Perri G
Clin Infect Dis; 2008 Jan; 46(1):146-7. PubMed ID: 18171231
[No Abstract] [Full Text] [Related]
32. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
35. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.
Chaubey SK; Sinha AK; Phillips E; Russell DB; Falhammar H
Sex Health; 2009 Sep; 6(3):254-7. PubMed ID: 19653965
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
38. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
[TBL] [Abstract][Full Text] [Related]
39. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
Iwamoto M; Wenning LA; Mistry GC; Petry AS; Liou SY; Ghosh K; Breidinger S; Azrolan N; Gutierrez MJ; Bridson WE; Stone JA; Gottesdiener KM; Wagner JA
Clin Infect Dis; 2008 Jul; 47(1):137-40. PubMed ID: 18513146
[TBL] [Abstract][Full Text] [Related]
40. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
Sahali S; Chaix ML; Delfraissy JF; Ghosn J
AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
